[{"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed131", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed131-001", "question": "A 54-year-old man with metastatic KRAS G12C-mutant non-small cell lung cancer (NSCLC) previously treated with platinum-doublet chemotherapy plus pembrolizumab achieves a partial response for 10 months and then develops radiographic progression in lung and liver. Next-generation sequencing on a liver biopsy shows persistent KRAS G12C, a new MET amplification (copy number 9), and no other targetable alterations. PD-L1 TPS is 80%. He is ECOG 1 with adequate organ function. Which of the following is the most appropriate next-line systemic therapy strategy?\n\nA. Switch to docetaxel and ramucirumab\nB. Start adagrasib monotherapy targeting KRAS G12C\nC. Enroll in a clinical trial of KRAS G12C inhibitor plus MET inhibitor combination\nD. Restart pembrolizumab monotherapy at an increased dose\nE. Use carboplatin, paclitaxel, and bevacizumab re-induction", "options": ["Switch to docetaxel and ramucirumab", "Start adagrasib monotherapy targeting KRAS G12C", "Enroll in a clinical trial of KRAS G12C inhibitor plus MET inhibitor combination", "Restart pembrolizumab monotherapy at an increased dose", "Use carboplatin, paclitaxel, and bevacizumab re-induction"], "answer": "C", "answer_index": 2, "explanation": "Emergent MET amplification is a known resistance mechanism to KRAS G12C inhibitors, and early data suggest combined KRAS G12C plus MET blockade may overcome resistance, making a combination clinical trial the most rational choice. Adagrasib monotherapy (B) will likely be undermined by the MET-driven bypass track. Docetaxel/ramucirumab (A) is standard chemo after immunotherapy but ignores a newly actionable resistance pathway in a trial-eligible patient. Pembrolizumab dose escalation (D) and re-induction platinum doublet with bevacizumab (E) are unlikely to benefit after clear progression on prior chemoimmunotherapy.", "generator_model": "gpt-5.1-2025-11-13", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: U/M. Verdict on keyed answer: Not uniquely determinable, though C is reasonable as a teaching point. Key stem clues: metastatic KRAS G12C NSCLC; prior platinum + pembrolizumab with progression; persistent KRAS G12C; new MET amplification (copy number 9); ECOG 1; PD-L1 80%; trial-eligible. The question asks for the most appropriate next‑line systemic therapy. Scientifically, MET amplification is a bypass resistance mechanism to KRAS G12C inhibition, so a combination KRAS G12C + MET inhibitor trial (C) is biologically rational. However, the resistance described is to prior chemo‑immunotherapy, not to a KRAS G12C inhibitor; the explanation incorrectly states emergent MET amplification is a resistance mechanism to KRAS G12C inhibitors rather than to upstream therapy. In current standard practice, FDA‑approved next line after chemo‑immunotherapy in KRAS G12C NSCLC is a KRAS G12C inhibitor (e.g., adagrasib), making B a very defensible best answer, while C is investigational. Thus there are two plausible “best” answers (approved targeted therapy vs. theoretical trial option) and the vignette does not clearly prioritize trial enrollment over established targeted therapy. Minimal fix: clarify he progressed on prior KRAS G12C inhibitor and explicitly state that an appropriate trial is available, or change key to B and adjust rationale accordingly.\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U/M. Verdict on keyed answer: Not uniquely determinable, though C is reasonable as a teaching point. Key stem clues: metastatic KRAS G12C NSCLC; prior platinum + pembrolizumab with progression; persistent KRAS G12C; new MET amplification (copy number 9); ECOG 1; PD-L1 80%; trial-eligible. The question asks for the most appropriate next‑line systemic therapy. Scientifically, MET amplification is a bypass resistance mechanism to KRAS G12C inhibition, so a combination KRAS G12C + MET inhibitor trial (C) is biologically rational. However, the resistance described is to prior chemo‑immunotherapy, not to a KRAS G12C inhibitor; the explanation incorrectly states emergent MET amplification is a resistance mechanism to KRAS G12C inhibitors rather than to upstream therapy. In current standard practice, FDA‑approved next line after chemo‑immunotherapy in KRAS G12C NSCLC is a KRAS G12C inhibitor (e.g., adagrasib), making B a very defensible best answer, while C is investigational. Thus there are two plausible “best” answers (approved targeted therapy vs. theoretical trial option) and the vignette does not clearly prioritize trial enrollment over established targeted therapy. Minimal fix: clarify he progressed on prior KRAS G12C inhibitor and explicitly state that an appropriate trial is available, or change key to B and adjust rationale accordingly.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed131", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed131-002", "question": "A 37-year-old woman develops generalized urticaria, throat tightness, and hypotension within 10 minutes of receiving a first infusion of rituximab for relapsed follicular lymphoma. Symptoms resolve completely with epinephrine, antihistamines, and steroids; tryptase 90 minutes after onset is elevated. Skin testing later shows strong positive intradermal response to rituximab at non-irritating concentrations. She requires anti-CD20 therapy for disease control and has failed obinutuzumab. Which is the most appropriate management of her need for B-cell-depleting therapy?\n\nA. Avoid all monoclonal antibodies and use lenalidomide alone\nB. Perform rapid drug desensitization to rituximab under intensive monitoring\nC. Premedicate with high-dose steroids and retry rituximab at 10% of standard rate without desensitization\nD. Switch to ofatumumab without further allergy evaluation\nE. Use omalizumab for 3 months before rechallenging with rituximab at full dose", "options": ["Avoid all monoclonal antibodies and use lenalidomide alone", "Perform rapid drug desensitization to rituximab under intensive monitoring", "Premedicate with high-dose steroids and retry rituximab at 10% of standard rate without desensitization", "Switch to ofatumumab without further allergy evaluation", "Use omalizumab for 3 months before rechallenging with rituximab at full dose"], "answer": "B", "answer_index": 1, "explanation": "Positive skin testing and elevated tryptase confirm IgE-mediated anaphylaxis to rituximab; the standard of care when the culprit agent is uniquely needed is a rapid desensitization protocol in a specialized setting. Premedication and slow infusion without desensitization (C) is unsafe in IgE-mediated reactions. Cross-reactivity among anti-CD20 mAbs is unpredictable, so empiric switch to ofatumumab (D) risks repeat anaphylaxis. Omalizumab pretreatment (E) is not a substitute for true desensitization. Completely abandoning monoclonals (A) compromises optimal lymphoma care without necessity.", "generator_model": "gpt-5.1-2025-11-13", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Allergy/Immunology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Immediate-onset urticaria, throat tightness, hypotension within 10 minutes of first rituximab infusion; complete response to anaphylaxis treatment; elevated tryptase at 90 minutes; positive intradermal skin test to rituximab at non-irritating concentrations; ongoing need for anti-CD20 therapy; failure of obinutuzumab. These findings strongly support IgE-mediated rituximab anaphylaxis with necessity to continue the culprit drug.\\nOption B is best because rapid drug desensitization to the culprit biologic in a specialized, closely monitored setting is the established standard when the agent is uniquely needed in IgE-mediated reactions.\\nOther options: A inappropriately abandons optimal monoclonal-based lymphoma therapy. C (premedication + slower rate without desensitization) is unsafe after confirmed IgE-mediated anaphylaxis. D ignores unpredictable cross-reactivity among anti-CD20 mAbs and bypasses indicated desensitization. E: omalizumab may be adjunctive in some protocols but is not evidence-based as a standalone substitute for formal desensitization.\\nMain medical issues: Content is consistent with current allergy/immunology and oncology standards; no major inaccuracies identified.\\nMinimal fix: State explicitly that desensitization resources are available at her treating center to preempt concerns about feasibility and reinforce B as clearly optimal.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Immediate-onset urticaria, throat tightness, hypotension within 10 minutes of first rituximab infusion; complete response to anaphylaxis treatment; elevated tryptase at 90 minutes; positive intradermal skin test to rituximab at non-irritating concentrations; ongoing need for anti-CD20 therapy; failure of obinutuzumab. These findings strongly support IgE-mediated rituximab anaphylaxis with necessity to continue the culprit drug.\nOption B is best because rapid drug desensitization to the culprit biologic in a specialized, closely monitored setting is the established standard when the agent is uniquely needed in IgE-mediated reactions.\nOther options: A inappropriately abandons optimal monoclonal-based lymphoma therapy. C (premedication + slower rate without desensitization) is unsafe after confirmed IgE-mediated anaphylaxis. D ignores unpredictable cross-reactivity among anti-CD20 mAbs and bypasses indicated desensitization. E: omalizumab may be adjunctive in some protocols but is not evidence-based as a standalone substitute for formal desensitization.\nMain medical issues: Content is consistent with current allergy/immunology and oncology standards; no major inaccuracies identified.\nMinimal fix: State explicitly that desensitization resources are available at her treating center to preempt concerns about feasibility and reinforce B as clearly optimal.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed131", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed131-003", "question": "An 88-year-old woman with frailty (Clinical Frailty Scale 6), CKD stage 3b, and mild Alzheimer disease is hospitalized for community-acquired pneumonia and recovers. She takes amlodipine, sertraline, donepezil, and PRN zolpidem. MMSE is 22/30; she ambulates with a walker and requires help with IADLs but is independent in basic ADLs. Her son asks about starting an intensive multifactorial fall-prevention program including high-dose vitamin D, hip protectors, supervised strength training 5 days/week, and environmental modifications. She has had no falls in the past year. Which recommendation is most appropriate?\n\nA. Recommend the full multifactorial program as requested\nB. Recommend only home environmental modifications and medication review\nC. Start high-dose vitamin D and hip protectors, but avoid exercise\nD. Defer interventions until she has at least one documented fall\nE. Prescribe low-dose benzodiazepine for sleep to reduce nocturnal wandering and falls", "options": ["Recommend the full multifactorial program as requested", "Recommend only home environmental modifications and medication review", "Start high-dose vitamin D and hip protectors, but avoid exercise", "Defer interventions until she has at least one documented fall", "Prescribe low-dose benzodiazepine for sleep to reduce nocturnal wandering and falls"], "answer": "B", "answer_index": 1, "explanation": "In very old, frail adults without a prior fall, targeted interventions-environmental modification and medication optimization-are recommended; high-intensity exercise programs can be burdensome and potentially risky without clear evidence of benefit in this subgroup. High-dose vitamin D (C) has not consistently reduced falls and may increase adverse events. Waiting for a first fall (D) misses the opportunity for primary prevention. Benzodiazepines (E) increase fall and delirium risk. The requested high-frequency supervised strength training (A) is unlikely to be practical or proportionate for her frailty and goals.", "generator_model": "gpt-5.1-2025-11-13", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Geriatrics", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 88-year-old, frail (CFS 6), CKD 3b, mild Alzheimer disease (MMSE 22), assistance with IADLs but independent in basic ADLs, no falls in past year, family requesting intensive multifactorial fall-prevention program including high-dose vitamin D, hip protectors, and supervised strength training 5 days/week, plus environmental changes.\\nThese findings place her at increased fall risk but also highlight limited reserve and potential burden from high-intensity, frequent supervised exercise. Current geriatric fall-prevention guidance supports primary prevention with low-burden, high-yield interventions such as home/environmental modification and medication review/optimization, especially regarding sedatives (zolpidem) and polypharmacy, while avoiding benzodiazepines.\\nOption B aligns with this: it provides proportionate, evidence-based primary prevention without excessive treatment burden or unproven high-dose vitamin D. A is overly intensive and includes non–evidence-based components (high-dose vitamin D, very frequent supervised strength training). C is poor because it omits exercise and uses high-dose vitamin D, which is not clearly beneficial and may be harmful. D misses primary prevention opportunities. E is contraindicated due to increased fall, delirium, and cognitive risks.\\nMinimal fix: Specify an example “high-dose” vitamin D regimen (e.g., ≥4000 IU/day or intermittent megadose) to avoid ambiguity about dosing thresholds.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 88-year-old, frail (CFS 6), CKD 3b, mild Alzheimer disease (MMSE 22), assistance with IADLs but independent in basic ADLs, no falls in past year, family requesting intensive multifactorial fall-prevention program including high-dose vitamin D, hip protectors, and supervised strength training 5 days/week, plus environmental changes.\nThese findings place her at increased fall risk but also highlight limited reserve and potential burden from high-intensity, frequent supervised exercise. Current geriatric fall-prevention guidance supports primary prevention with low-burden, high-yield interventions such as home/environmental modification and medication review/optimization, especially regarding sedatives (zolpidem) and polypharmacy, while avoiding benzodiazepines.\nOption B aligns with this: it provides proportionate, evidence-based primary prevention without excessive treatment burden or unproven high-dose vitamin D. A is overly intensive and includes non–evidence-based components (high-dose vitamin D, very frequent supervised strength training). C is poor because it omits exercise and uses high-dose vitamin D, which is not clearly beneficial and may be harmful. D misses primary prevention opportunities. E is contraindicated due to increased fall, delirium, and cognitive risks.\nMinimal fix: Specify an example “high-dose” vitamin D regimen (e.g., ≥4000 IU/day or intermittent megadose) to avoid ambiguity about dosing thresholds.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed131", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed131-004", "question": "A 62-year-old woman with newly diagnosed metastatic ER-positive, HER2-negative breast cancer involving bone and liver has a germline PALB2 truncating mutation and no BRCA1/2 mutation. She is postmenopausal, has not received prior systemic therapy for metastatic disease, and had adjuvant tamoxifen 15 years ago. ECOG is 0. Liver disease burden is moderate, without imminent organ failure. Which initial systemic treatment strategy is most appropriate?\n\nA. Aromatase inhibitor plus CDK4/6 inhibitor\nB. Single-agent PARP inhibitor targeting PALB2 mutation\nC. Weekly paclitaxel chemotherapy\nD. Fulvestrant monotherapy\nE. Tamoxifen plus ovarian suppression", "options": ["Aromatase inhibitor plus CDK4/6 inhibitor", "Single-agent PARP inhibitor targeting PALB2 mutation", "Weekly paclitaxel chemotherapy", "Fulvestrant monotherapy", "Tamoxifen plus ovarian suppression"], "answer": "A", "answer_index": 0, "explanation": "For first-line metastatic ER+/HER2- disease without visceral crisis, an aromatase inhibitor plus CDK4/6 inhibitor remains standard even in carriers of non-BRCA homologous recombination gene mutations such as PALB2. While PARP inhibitors show activity in PALB2, they are not yet standard first-line outside trials (B). Chemotherapy (C) is reserved for endocrine-refractory or visceral crisis cases. Fulvestrant monotherapy (D) is inferior to CDK4/6-based combinations. Tamoxifen with ovarian suppression (E) is inappropriate in a postmenopausal woman and is less effective than aromatase inhibition.", "generator_model": "gpt-5.1-2025-11-13", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Postmenopausal woman; newly diagnosed metastatic ER-positive, HER2-negative breast cancer; bone and liver metastases but no visceral crisis (“moderate” liver burden, ECOG 0, no imminent organ failure); prior adjuvant tamoxifen many years ago; germline PALB2 truncating mutation, BRCA1/2 negative; no prior systemic therapy for metastatic disease.\\nThese features point to standard first-line endocrine-based therapy for HR+/HER2− MBC without visceral crisis. Current guidelines support an aromatase inhibitor plus CDK4/6 inhibitor as preferred initial systemic therapy. PARP inhibitors have activity in PALB2-mutated tumors but are not established first-line standard in PALB2 without BRCA1/2. Chemotherapy is reserved for endocrine-refractory disease or visceral crisis. Fulvestrant monotherapy is less effective than combinations with CDK4/6 and is not preferred front line in this setting. Tamoxifen plus ovarian suppression is inappropriate because the patient is postmenopausal and aromatase inhibition is superior.\\nNo major internal contradictions; the key matches the unique best choice (A). Medical content aligns with contemporary practice patterns and evidence.\\nMinimal fix: Explicitly note in the stem that the patient is not in visceral crisis to make the rationale for avoiding upfront chemotherapy even clearer, though it is already implied.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Postmenopausal woman; newly diagnosed metastatic ER-positive, HER2-negative breast cancer; bone and liver metastases but no visceral crisis (“moderate” liver burden, ECOG 0, no imminent organ failure); prior adjuvant tamoxifen many years ago; germline PALB2 truncating mutation, BRCA1/2 negative; no prior systemic therapy for metastatic disease.\nThese features point to standard first-line endocrine-based therapy for HR+/HER2− MBC without visceral crisis. Current guidelines support an aromatase inhibitor plus CDK4/6 inhibitor as preferred initial systemic therapy. PARP inhibitors have activity in PALB2-mutated tumors but are not established first-line standard in PALB2 without BRCA1/2. Chemotherapy is reserved for endocrine-refractory disease or visceral crisis. Fulvestrant monotherapy is less effective than combinations with CDK4/6 and is not preferred front line in this setting. Tamoxifen plus ovarian suppression is inappropriate because the patient is postmenopausal and aromatase inhibition is superior.\nNo major internal contradictions; the key matches the unique best choice (A). Medical content aligns with contemporary practice patterns and evidence.\nMinimal fix: Explicitly note in the stem that the patient is not in visceral crisis to make the rationale for avoiding upfront chemotherapy even clearer, though it is already implied.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed131", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed131-005", "question": "A 29-year-old man has a history of recurrent severe bacterial sinopulmonary infections since childhood, requiring multiple hospitalizations. At age 20 he was diagnosed with common variable immunodeficiency (CVID) based on hypogammaglobulinemia and poor vaccine responses and was started on IVIG, which reduced infections. Over the last 2 years he has developed splenomegaly, autoimmune hemolytic anemia, and noncaseating granulomas on lung biopsy. Lymph node biopsy now shows nodular lymphoid hyperplasia without lymphoma. Flow cytometry reveals near absence of class-switched memory B cells and elevated CD21low B cells. Which underlying mechanistic subtype of CVID best explains his course and complications?\n\nA. Predominantly T-cell signaling defect with normal B-cell maturation\nB. B-cell intrinsic impairment of terminal differentiation and class-switch recombination\nC. Isolated defect of BAFF signaling with expanded naïve B cells\nD. Hyperactive regulatory T cells causing global immunosuppression\nE. Primary phagocyte oxidase deficiency leading to impaired respiratory burst", "options": ["Predominantly T-cell signaling defect with normal B-cell maturation", "B-cell intrinsic impairment of terminal differentiation and class-switch recombination", "Isolated defect of BAFF signaling with expanded naïve B cells", "Hyperactive regulatory T cells causing global immunosuppression", "Primary phagocyte oxidase deficiency leading to impaired respiratory burst"], "answer": "B", "answer_index": 1, "explanation": "CVID patients with absent class-switched memory B cells and increased CD21low B cells have B-cell intrinsic defects in terminal differentiation/class switching and are prone to autoimmunity, granulomatous disease, and lymphoid hyperplasia, matching this case. Predominant T-cell signaling defects (A) generally show more opportunistic infections. BAFF pathway defects (C) usually present with different B-cell phenotypes. Excess Treg activity (D) does not explain the specific B-cell abnormalities. Phagocyte oxidase deficiency (E) characterizes chronic granulomatous disease, not CVID with hypogammaglobulinemia and poor vaccine responses.", "generator_model": "gpt-5.1-2025-11-13", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Allergy/Immunology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Longstanding CVID with hypogammaglobulinemia and poor vaccine responses; recurrent sinopulmonary bacterial infections improved with IVIG; new complications of splenomegaly, autoimmune hemolytic anemia, granulomatous lung disease, and nodular lymphoid hyperplasia; immunophenotype shows near absence of class-switched memory B cells and increased CD21low B cells. This phenotype is well described as a B‑cell–intrinsic defect in terminal differentiation and class-switch recombination and is associated with autoimmunity, granulomas, and lymphoid hyperplasia.\\nOption analysis: (B) directly matches the known CVID mechanistic subtype linked to these features. (A) T-cell signaling defects in CVID are associated with more severe/opportunistic infections and do not specifically predict this B-cell subset pattern. (C) Isolated BAFF signaling defects are not the typical mechanism of classic CVID and have different B-cell phenotypes. (D) Hyperactive Tregs with “global immunosuppression” is not a standard CVID mechanism nor tied to this B-cell profile. (E) Describes chronic granulomatous disease, which would not cause hypogammaglobulinemia and poor vaccine responses.\\nMain medical/logical issues: None significant; item is specific and up-to-date.\\nMinimal fix: Clarify in stem that genetic testing excluded other defined primary immunodeficiencies to reinforce this as a CVID subtype question, not a misclassification of another disorder.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Longstanding CVID with hypogammaglobulinemia and poor vaccine responses; recurrent sinopulmonary bacterial infections improved with IVIG; new complications of splenomegaly, autoimmune hemolytic anemia, granulomatous lung disease, and nodular lymphoid hyperplasia; immunophenotype shows near absence of class-switched memory B cells and increased CD21low B cells. This phenotype is well described as a B‑cell–intrinsic defect in terminal differentiation and class-switch recombination and is associated with autoimmunity, granulomas, and lymphoid hyperplasia.\nOption analysis: (B) directly matches the known CVID mechanistic subtype linked to these features. (A) T-cell signaling defects in CVID are associated with more severe/opportunistic infections and do not specifically predict this B-cell subset pattern. (C) Isolated BAFF signaling defects are not the typical mechanism of classic CVID and have different B-cell phenotypes. (D) Hyperactive Tregs with “global immunosuppression” is not a standard CVID mechanism nor tied to this B-cell profile. (E) Describes chronic granulomatous disease, which would not cause hypogammaglobulinemia and poor vaccine responses.\nMain medical/logical issues: None significant; item is specific and up-to-date.\nMinimal fix: Clarify in stem that genetic testing excluded other defined primary immunodeficiencies to reinforce this as a CVID subtype question, not a misclassification of another disorder.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed131", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed131-006", "question": "A 91-year-old man with advanced heart failure (EF 25%), CKD stage 4, and severe osteoarthritis lives in a nursing home. He has moderate dementia (MoCA 15/30), needs help with all IADLs and most ADLs, and has had three hospitalizations in 6 months. He has a POLST specifying do-not-resuscitate/do-not-intubate and refusal of ICU care. His daughter, the health care proxy, asks about starting an SGLT2 inhibitor recently recommended by cardiology to reduce heart failure hospitalizations. He has had recurrent genital candidiasis and baseline systolic BPs around 100 mmHg. What is the most appropriate geriatric-focused response?\n\nA. Start the SGLT2 inhibitor because hospitalization reduction is a priority outcome at any life expectancy\nB. Defer the SGLT2 inhibitor due to limited life expectancy, hypotension risk, and alignment with comfort-focused goals\nC. Start the SGLT2 inhibitor at half dose and monitor blood pressure weekly\nD. Replace his loop diuretic with the SGLT2 inhibitor to reduce polypharmacy\nE. Recommend ICU-level monitoring for the first month of SGLT2 therapy", "options": ["Start the SGLT2 inhibitor because hospitalization reduction is a priority outcome at any life expectancy", "Defer the SGLT2 inhibitor due to limited life expectancy, hypotension risk, and alignment with comfort-focused goals", "Start the SGLT2 inhibitor at half dose and monitor blood pressure weekly", "Replace his loop diuretic with the SGLT2 inhibitor to reduce polypharmacy", "Recommend ICU-level monitoring for the first month of SGLT2 therapy"], "answer": "B", "answer_index": 1, "explanation": "In very old, frail patients with advanced multimorbidity, limited life expectancy, and clear preferences against aggressive interventions, guideline-directed therapies with delayed or modest benefit (such as SGLT2 inhibitors) should be reconsidered when risks (hypotension, infections, AKI) and treatment burden outweigh likely gains. Dose reduction (C) does not eliminate these concerns and still adds complexity. Replacing loop diuretics (D) would worsen volume control. ICU monitoring (E) contradicts his POLST. Automatically prioritizing hospitalization reduction (A) ignores his comfort-focused goals and short prognosis.", "generator_model": "gpt-5.1-2025-11-13", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Geriatrics", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 91 years old, advanced HFrEF (EF 25%), CKD4, severe osteoarthritis, moderate dementia, total dependence in IADLs and most ADLs, multiple recent hospitalizations, POLST with DNR/DNI and refusal of ICU-level care, recurrent genital candidiasis, baseline systolic BP ~100 mmHg, and daughter asking about starting SGLT2 inhibitor to reduce HF hospitalizations. These indicate very limited life expectancy, high frailty, comfort-oriented goals, and elevated risks from SGLT2 therapy (hypotension, genital infections, AKI) with relatively delayed/uncertain benefit.\\nOption B appropriately recommends deferring the SGLT2 inhibitor, explicitly tying the decision to geriatric principles of prognosis, risk–benefit, and goal-concordant care.\\nOption A ignores prognosis and stated comfort focus. Option C continues a questionable therapy and does not meaningfully mitigate risks or treatment burden. Option D misuses SGLT2 as a loop diuretic substitute, which is incorrect clinically. Option E directly conflicts with the POLST and is not indicated.\\nNo internal contradictions or missing critical details; one clearly superior answer.\\nMinimal fix: Clarify that his overall goals have been explicitly documented as comfort-focused/palliative to make the goal-concordant reasoning even more explicit, though the item is already functionally clear.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 91 years old, advanced HFrEF (EF 25%), CKD4, severe osteoarthritis, moderate dementia, total dependence in IADLs and most ADLs, multiple recent hospitalizations, POLST with DNR/DNI and refusal of ICU-level care, recurrent genital candidiasis, baseline systolic BP ~100 mmHg, and daughter asking about starting SGLT2 inhibitor to reduce HF hospitalizations. These indicate very limited life expectancy, high frailty, comfort-oriented goals, and elevated risks from SGLT2 therapy (hypotension, genital infections, AKI) with relatively delayed/uncertain benefit.\nOption B appropriately recommends deferring the SGLT2 inhibitor, explicitly tying the decision to geriatric principles of prognosis, risk–benefit, and goal-concordant care.\nOption A ignores prognosis and stated comfort focus. Option C continues a questionable therapy and does not meaningfully mitigate risks or treatment burden. Option D misuses SGLT2 as a loop diuretic substitute, which is incorrect clinically. Option E directly conflicts with the POLST and is not indicated.\nNo internal contradictions or missing critical details; one clearly superior answer.\nMinimal fix: Clarify that his overall goals have been explicitly documented as comfort-focused/palliative to make the goal-concordant reasoning even more explicit, though the item is already functionally clear.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]